Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients

International Journal of Antimicrobial Agents

Volumn 33, Issue 3, 2009, Pages 276-279

  Ikawa, Kazuro ^a   Morikawa, Norifumi ^a   Uehara, Shinya ^b   Monden, Koichi ^b   Yamada, Yoshiaki ^c   Honda, Nobuaki ^c   Kumon, Hiromi ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breakpoint; Carbapenem; Monte Carlo simulation; Population pharmacokinetics; Probability of target attainment

Indexed keywords

DORIPENEM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG INFUSION; DRUG URINE LEVEL; FEMALE; HUMAN; INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COMPUTER SIMULATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PLASMA; TIME FACTORS; URINE;

EID: 60249084774     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.08.031     Document Type: Article

References (12)

1. Greer N.D. Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent) 21 (2008) 337-341
2. Bhavnani S.M., Hammel J.P., Cirincione B.B., Wikler M.A., and Ambrose P.G. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 49 (2005) 3944-3947
3. Watanabe A., Fujimura S., Kikuchi T., Gomi K., Fuse K., and Nukiwa T. Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation. J Infect Chemother 13 (2007) 332-340
4. Nagasawa Z., Kusaba K., and Aoki Y. Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation. J Infect Chemother 14 (2008) 238-243
5. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modelling and Monte Carlo simulation. Diagn Microbiol Infect Dis 2008;62:292-7.
6. Nakashima M., and Oguma T. Phase I study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers. Jpn J Chemother 53 Suppl. (2005) 104-123
7. Ikeda K., Ikawa K., Morikawa N., Kameda K., Urakawa N., Ohge H., et al. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Anal Technol Biomed Life Sci 867 (2008) 20-25
8. Mouton J.W., Dudley M.N., Cars O., Derendorf H., and Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55 (2005) 601-607
9. Kim A., Banevicius M.A., and Nicolau D.P. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 52 (2008) 2497-2502
10. Frei C.R., Wiederhold N.P., and Burgess D.S. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61 (2008) 621-628
11. Ortho-McNeil-Janssen Pharmaceuticals. DORIBAX™ (doripenem for injection) package insert. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals; 2008. http://www.doribax.com/doribax/interactive_pi.html [accessed 26 September 2008].
12. Fritsche T.R., Stilwell M.G., and Jones R.N. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 11 (2005) 974-984